NuCana (NASDAQ:NCNA) Announces Quarterly Earnings Results

NuCana (NASDAQ:NCNA) released its quarterly earnings data on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.43) by $2.11, Zacks reports.

NuCana Stock Performance

NASDAQ NCNA traded down $0.04 during trading hours on Thursday, hitting $0.81. The company had a trading volume of 30,468 shares, compared to its average volume of 419,989. NuCana has a 1-year low of $0.75 and a 1-year high of $10.79. The company has a market cap of $2.13 million, a PE ratio of -0.08 and a beta of 0.89. The business has a 50 day moving average of $0.98 and a 200-day moving average of $1.57.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.